Skip to content

Study · Randomized controlled trial · n = 13 · 2020

3 results

A Preliminary Examination of Endogenous Peripheral Oxytocin in a Pilot Randomized Clinical Trial of Oxytocin-Enhanced Psychotherapy for Posttraumatic Stress Disorder.

Sippel LM, King CE, Wahlquist AE, Flanagan JC

Journal of clinical psychopharmacology1 Jul 2020Cited by 7 (Europe PMC)

PMID32639293 (opens in a new tab)PMCIDPMC7350551 (opens in a new tab)DOI10.1097/jcp.0000000000001226 (opens in a new tab)PepBankPUB-32639293
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In people with PTSD receiving prolonged exposure therapy, the change in peripheral oxytocin levels did not differ between adjunctive intranasal oxytocin and placebo.

    In plain wordsIn people with PTSD, blood oxytocin levels changed no differently with intranasal oxytocin than with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeChange in peripheral oxytocin levels by treatment condition
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Change in peripheral oxytocin levels did not differ by treatment condition
    1 context sentence
    Summary · context
    In the current study, we examined associations between PTSD symptom severity and peripheral oxytocin levels measured in plasma before and after a course of prolonged exposure (PE) for PTSD (n = 13); participants were randomized to adjunctive intranasal oxytocin (n = 6) or placebo (n = 7).

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 02HumanEndogenous levelRandomized controlled trialMechanism

    In people with PTSD, baseline plasma levels of the body's own oxytocin were not associated with baseline PTSD symptom severity.

    In plain wordsIn people with PTSD, natural oxytocin levels in blood were not linked to how severe symptoms were at the start.

    Peptide
    Oxytocin
    Outcome
    No significant changeBaseline peripheral oxytocin and baseline PTSD symptom severity
    Study

    n = 13

    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    Baseline peripheral oxytocin levels were not associated with baseline PTSD symptom severity.
    1 context sentence
    Summary · context
    In the current study, we examined associations between PTSD symptom severity and peripheral oxytocin levels measured in plasma before and after a course of prolonged exposure (PE) for PTSD (n = 13); participants were randomized to adjunctive intranasal oxytocin (n = 6) or placebo (n = 7).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 03HumanEndogenous levelRandomized controlled trialMechanism

    In people with PTSD, change in the body's own peripheral oxytocin levels did not correspond to change in PTSD symptoms.

    In plain wordsIn people with PTSD, changes in natural oxytocin levels did not match changes in symptoms.

    Peptide
    Oxytocin
    Outcome
    No significant changeChange in peripheral oxytocin and change in PTSD symptoms
    Study

    n = 13

    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    and did not correspond to change in PTSD symptoms.
    1 context sentence
    Summary · context
    In the current study, we examined associations between PTSD symptom severity and peripheral oxytocin levels measured in plasma before and after a course of prolonged exposure (PE) for PTSD (n = 13); participants were randomized to adjunctive intranasal oxytocin (n = 6) or placebo (n = 7).

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.